Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAM2029 in Acute Respiratory Distress Syndrome (ARDS)
2021-000598-95Phase 2Terminated
- Sponsor
- Camurus
- Start
- May 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing CAM2029 with Placebo (2 arms). Primary endpoint: Time to improvement in oxygenation saturation index (≥ 2.0) sustained for at least 48 hours. Started May 2021; status: terminated.
02
Drugs
octreotide hydrochloride
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2021-000598-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000598-95.